Table 3.

Subgroup analysis of the association between RAD51C and breast cancer by ovarian cancer family history and hormone receptor status

Personal/family history	Familial breast cancer cases			Cancer-free controls			OR (95% CI)*	P†
	RAD51C	Frequency, %	Total	RAD51C	Frequency, %	Total
All subjects	11	0.4	3080	2	0.04	4840	8.67 (1.89 to 80.52)	<.001
Have OvCa history‡	5	0.8	638	2	0.04	4840	19.09 (3.12 to 200.42)	<.001
Excluding OvCa history§	6	0.2	2442	2‖	0.04	4840	5.96 (1.06 to 60.42)	.02
ER+ breast cancer	3	0.2	1726	2	0.04	4840	4.21(0.48 to 50.44)	.12
ER− breast cancer	8	0.8	939	2	0.04	4840	20.77 (4.14 to 200.58)	<.001
Triple-negative breast cancer	7	1.1	626	2	0.04	4840	27.33 (5.19 to 268.54)	<.001

^*The ORs for each subgroup analysis were calculated using the reference group of cancer-free controls. CI = confidence interval; ER = estrogen; OR = odds ratio; OvCa = ovarian cancer.

^†Fisher exact test, 2-sided.

^‡Ovarian cancer diagnosis in the index case of one or more first- to third-degree relatives.

^§No ovarian cancer diagnosis in the index case or any first- to third-degree relative.

^‖Both of these control carriers reported having first- and/or second-degree relatives diagnosed with breast and/or ovarian cancer: One control carrier reported a sister diagnosed with breast cancer (age 45 years) and another sister diagnosed with ovarian cancer (age unknown). The other control carrier reported her mother was diagnosed with both breast cancer (age 30 years) and ovarian cancer (age 49) and that “multiple” second-degree relatives were diagnosed with breast or ovarian cancer (age unknown).